Two Sigma Advisers
SPRO icon

Two Sigma Advisers’s Spero Therapeutics SPRO Stock Holding History

Two Sigma Advisers’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-216,600
Closed -$505K – 1848
2025
Q4 		$505K Buy
+216,600
New +$503K ﹤0.01% 1775
2022
Q3 		– Sell
-176,157
Closed -$131K – 2717
2022
Q2 		$131K Buy
176,157
+159,757
+974% +$465K ﹤0.01% 2357
2022
Q1 		$143K Buy
+16,400
New +$168K ﹤0.01% 2441
2021
Q2 		– Sell
-24,528
Closed -$361K – 2679
2021
Q1 		$361K Buy
24,528
+5,200
+27% +$91.5K ﹤0.01% 2152
2020
Q4 		$375K Sell
19,328
-2,100
-10% -$32.7K ﹤0.01% 1972
2020
Q3 		$239K Buy
21,428
+5,100
+31% +$60.3K ﹤0.01% 2100
2020
Q2 		$221K Buy
+16,328
New +$183K ﹤0.01% 2214

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers's SPRO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 216,600 shares — an estimated $505K sold.

Two Sigma Advisers first reported a position in SPRO in Q2 2020 and held it in 7 quarters. The position peaked at $505K in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 216,600 Spero Therapeutics shares in Q1 2026, an estimated $505K.
  • Two Sigma Advisers first reported a position in Spero Therapeutics in Q2 2020 and held it in 7 quarters.
  • Two Sigma Advisers's Spero Therapeutics position peaked at $505K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.